May 5, 2022 08:00AM Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics

Feb 17, 2022 08:30AM Entera Bio to Present at Aegis Virtual Conference on February 23rd

Jan 4, 2022 08:32AM Entera Bio Ltd. (ENTX) Reports Successful EB613 End-of-Phase 2 Meeting with FDA; Agrees on Phase 3 Endpoints

Jan 4, 2022 08:30AM Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint

Nov 10, 2021 08:30AM Entera Bio Reports Third Quarter 2021 Financial Results

Oct 28, 2021 08:30AM Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs

Oct 6, 2021 08:36AM Entera Bio (ENTX) Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session

Oct 6, 2021 08:30AM Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session

Sep 1, 2021 08:30AM Entera Bio Selected for Late Breaking Oral Presentation of Phase 2 6-Month Osteoporosis Data at ASBMR 2021 Annual Meeting

Aug 23, 2021 11:00AM Entera Bio to Conduct Annual Shareholders Meeting on October 4, 2021

Aug 23, 2021 08:30AM Entera Bio to Present at H.C. Wainwright 23rd Annual Global Investment Conference

Aug 16, 2021 06:30AM Entera Bio Reports Second Quarter 2021 Financial Results and Provides Clinical Updates

Aug 2, 2021 08:30AM Entera Bio to Present Phase 2 EB613 Oral PTH Osteoporosis Treatment 3-Month Findings at the American Society for Bone and Mineral Research Annual Meeting

Jun 28, 2021 03:15PM Entera Bio to Conduct Conference Call on June 30 to Discuss Phase 2 Results for EB613 Positioned to be the First Oral Bone-Building Agent for the Treatment of Osteoporosis

Jun 23, 2021 08:33AM Entera Bio Ltd. (ENTX) Phase 2 BMD for EB613 Study Met Its Primary and Key Secondary Endpoints

Jun 23, 2021 08:30AM Entera Bio Announces Excellent Topline Phase 2 BMD Data for EB613, the Study Met Its Primary and Key Secondary Endpoints

Jun 17, 2021 08:00AM Entera Bio Receives Foundational Patent for its Oral PTH using its Platform Oral Protein Delivery Technology in European Union

May 20, 2021 08:00AM Entera Bio Reports First Quarter 2021 Financial Results and Provides Clinical Updates

Apr 20, 2021 08:46AM Entera Bio Ltd. (ENTX) Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors

Apr 20, 2021 08:45AM Entera Announces Ron Mayron, a Global Pharma Leader, Joins its Board of Directors

Apr 15, 2021 08:33AM Entera Bio Ltd. (ENTX) Names Ramesh Ratan CFO

Apr 15, 2021 08:30AM Entera Appoints Ramesh Ratan as Chief Financial Officer

Apr 6, 2021 08:30AM New Data Suggest Entera’s Platform Orally Delivers Human Growth Hormone, Study Results to be Presented at European Pharma Congress

Mar 18, 2021 08:00AM Entera Bio Ltd Announces Operating and Financial Results for the Fourth Quarter and Year Ended December 31, 2020

Mar 11, 2021 08:33AM Entera Bio Ltd. (ENTX) Announces Positive Topline EB613 Phase 2 Biomarker Data

Mar 11, 2021 08:30AM Entera Bio Ltd Announces Positive Topline EB613 Phase 2 Biomarker Data

Feb 25, 2021 08:39AM Entera Bio (ENTX) Announces Publication of Phase 2 Hypoparathyroidism Study in the Journal of Bone and Mineral Research

Feb 25, 2021 08:30AM Entera Bio Announces Publication of Phase 2 Hypoparathyroidism Study in the Journal of Bone and Mineral Research

Feb 8, 2021 08:31AM Entera Bio Ltd. (ENTX) Commences New Research Program For Oral GLP-2

Feb 8, 2021 08:30AM Entera Bio Initiates New Research Program For Oral GLP-2

Jan 11, 2021 08:36AM Entera Bio Ltd. (ENTX) Issues Letter to Shareholders

Jan 11, 2021 08:30AM Entera Bio Issues Letter to Shareholders

Dec 10, 2020 08:32AM Entera Bio (ENTX) Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis

Dec 10, 2020 08:30AM Entera Bio Announces FDA Approval of IND Application for EB613 – an Oral Human Parathyroid Hormone (1-34) for the Treatment of Osteoporosis

Nov 30, 2020 04:05PM Entera Bio Appoints Spiros Jamas as Chief Executive Officer

Nov 19, 2020 06:30AM Entera Bio Ltd Announces Third Quarter 2020 Financial Results and Provides Clinical Update

Nov 9, 2020 08:34AM Entera Bio Ltd. (ENTX) Reports Complete Patient Enrollment in Phase 2 Clinical Trial of Eb613 In Osteoporosis

Nov 9, 2020 08:30AM Entera Bio Ltd Announces Completion of Enrollment In Phase 2 Clinical Trial of Eb613 In Osteoporosis

Aug 20, 2020 06:33AM Entera Bio (ENTX) Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Q2 Financial Results

Aug 20, 2020 06:30AM Entera Bio Ltd Announces Interim Data From Phase 2 Clinical Trial of EB613 in Osteoporosis and Second Quarter 2020 Financial Results

Aug 10, 2020 08:35AM Entera Bio Ltd. (ENTX) appoints Roger Garceau as Interim CEO

Aug 10, 2020 08:30AM Entera Bio Announces Management Changes

Jul 22, 2020 04:05PM Entera Bio Ltd. Announces Highly Encouraging Oral PTH Market Survey Results

Jul 7, 2020 08:35AM Entera Bio (ENTX) Provides Update on Phase 2 Clinical Trial of EB613 in Postmenopausal Women With Osteoporosis

Jul 7, 2020 08:30AM Entera Bio Ltd Provides Update on Phase 2 Clinical Trial of EB613 in Postmenopausal Women With Osteoporosis

May 21, 2020 06:33AM Entera Bio Ltd. (ENTX) Reports Interim Biomarker Data From Phase 2 Clinical Trial of EB613

May 21, 2020 06:30AM Entera Bio Ltd Announces Interim Biomarker Data From Phase 2 Clinical Trial of EB613 and First Quarter 2020 Financial Results

Mar 26, 2020 06:30AM ENTERA BIO LTD ANNOUNCES FINANCIAL AND OPERATING RESULTS FOR THE FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2019